Core Viewpoint - Berkshire Hills Bancorp and Brookline Bancorp have received all necessary regulatory approvals to proceed with their merger, which will create a new entity named Beacon Financial Corporation, effective September 1, 2025 [1][2][3]. Group 1: Merger Details - The merger will result in a combined company valued at $24 billion, with over 145 branch offices serving the Northeast region [2]. - The regulatory approvals were granted by multiple authorities, including the Federal Reserve System and state banking departments [3]. - Shareholders of both companies approved the merger proposals during meetings held on May 21, 2025 [3]. Group 2: Leadership and Integration - Paul A. Perrault, CEO of Brookline, will lead the combined company as CEO, while David M. Brunelle of Berkshire will serve as Chairperson of the Board [4][5]. - The integration process is expected to be smooth, with both organizations having collaborated extensively in preparation for the merger [4]. Group 3: Brand Transition - Following the merger, the new entity will operate under the name Beacon Financial Corporation, with shares trading on the NYSE under the symbol "BBT" [5]. - Clients will continue to access services through their existing bank branches until a full transition to the Beacon Bank brand is completed, anticipated in the first quarter of 2026 [5][6].

EL SEGUNDO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- A-Mark Precious Metals, Inc. (NASDAQ: AMRK) (A-Mark), a leading fully integrated precious metals platform, will hold a conference call on Tuesday, September 9, 2025, at 4:30 p.m. Eastern time to discuss results for the fiscal fourth quarter and full year ended June 30, 2025. Financial results will be issued in a press release prior to the call. A-Mark management will host the presentation, followed by a question-and-answer period. A-Mark’s conference cal ...

Core Insights - NN, Inc. has appointed Mohamad Farhat as the new Chief Technical Officer for its electrical, defense, and medical businesses, aiming to enhance innovation and customer solutions [1][2][3] Company Overview - NN, Inc. is a global diversified industrial company that specializes in engineering and manufacturing high-precision components and assemblies for various markets [4] Leadership and Strategy - The appointment of Mr. Farhat is part of NN's strategy to strengthen its technical capabilities and innovation focus, particularly in the electrical, defense, and medical sectors [2][3] - Tim French, COO, emphasized the importance of technology leadership in solving customer problems and expanding into new markets [3] Market Focus - NN has a distinct focus on electrical, defense, and medical products, with recent promotions within the company to enhance its Mobile Solutions segment, which targets automotive and industrial markets [2][3] Background of New CTO - Mohamad Farhat brings extensive experience in engineering leadership, having previously served as Vice President of Engineering for Commercial Vehicle Group, Inc., and held roles at Sumitomo, Rigaku, and Flex [3]

Core Insights - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases [3] - The company will have its CEO, Warner Biddle, present at multiple upcoming healthcare conferences in September 2025 [1][2] Conference Details - Kyverna will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 11:00 a.m. ET [1] - The company will also participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 4:05 p.m. ET [1] - Additionally, Kyverna will be featured at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 a.m. ET [2] Company Pipeline - Kyverna's lead CAR T-cell therapy candidate, KYV-101, is in late-stage clinical development for stiff person syndrome and myasthenia gravis, with ongoing trials for lupus nephritis [3] - The company is also exploring other indications such as multiple sclerosis and rheumatoid arthritis through various trials [3] - Kyverna is developing next-generation CAR T-cell therapies in both autologous and allogeneic formats, aiming to expand into broader autoimmune indications [3]

Core Viewpoint - Navitas Semiconductor has appointed Chris Allexandre as the new President and CEO, effective September 1, 2025, succeeding founder Gene Sheridan, who will step down on August 31, 2025 [1][2]. Company Leadership Transition - Chris Allexandre brings over 25 years of semiconductor industry experience, having held senior roles at Renesas Electronics, where he managed a $2.5 billion power management business [2][3]. - Gene Sheridan has led Navitas for 11 years, establishing it as a leader in next-generation power semiconductors, particularly in GaN and SiC technologies [2][3]. Strategic Focus and Market Opportunities - Allexandre's leadership is expected to drive expansion in key markets such as AI data centers and energy infrastructure, which are critical for GaN and SiC technologies [3][10]. - The company aims to leverage its unique position in the power semiconductor market to capitalize on the growing demand for electrification solutions [10]. Company Background - Navitas Semiconductor, founded in 2014, is recognized as the only pure-play, next-generation power semiconductor company, focusing on GaNFast™ power ICs and GeneSiC™ silicon carbide devices [10]. - The company has over 300 patents issued or pending and was the first semiconductor company to achieve CarbonNeutral® certification [10].

Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly epilepsy [1][13] - The company utilizes proprietary small molecule and antisense oligonucleotide (ASO) platforms to address neurological disorders characterized by neuronal excitation-inhibition imbalance [13] Upcoming Event Participation - Praxis will participate in the International Epilepsy Congress (IEC) from August 30 to September 3, 2025, in Lisbon, Portugal, showcasing its advancements in epilepsy treatment [1][2] - The company plans to present topline results from the RADIANT study in focal onset seizures (FOS) and share updates on its precision epilepsy pipeline through twelve presentations [2][4] Research and Development Highlights - Vormatrigine, a small molecule targeting sodium channels, is being developed for adult focal onset seizures and generalized epilepsy, showing robust seizure reduction in clinical studies [4][8] - Relutrigine, a first-in-class small molecule for developmental and epileptic encephalopathies (DEEs), has demonstrated significant seizure control in preclinical models and received multiple designations from regulatory agencies [11][12] - Elsunersen, an ASO targeting SCN2A gene expression, has shown promise in reducing seizures and improving outcomes in SCN2A-DEE models, with ongoing studies under collaboration with Ionis Pharmaceuticals [12][13] Presentation Schedule - Praxis will conduct various presentations during the IEC, including platform and poster presentations, detailing the predictive validity of preclinical seizure models and updates from ongoing studies [3][6][10]

Company Announcement - Rent the Runway, Inc. plans to release its second quarter 2025 financial results on September 11, 2025, after market close [1] - A conference call and live webcast will be held at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update [1] Access Information - The financial results and live webcast will be accessible through the Investor Relations section of Rent the Runway's website [2] - To access the conference call, U.S. callers can dial 1-877-407-3982, while international callers can use 1-201-493-6780 [2] Replay Details - A replay of the conference call will be available shortly after the call for at least fourteen days [3] - U.S. callers can access the replay by dialing 1-844-512-2921, and international callers can use 1-412-317-6671 with access code 13755468 [3] Company Overview - Founded in 2009, Rent the Runway is transforming the fashion industry with its "Closet in the Cloud" concept [4] - The company offers subscription services, a-la-carte rentals, and resale options from hundreds of designer brands, featuring millions of items for various occasions [4] - Under the leadership of CEO Jennifer Hyman, Rent the Runway has received multiple accolades, including being named to CNBC's "Disruptor 50" five times and Fast Company's Most Innovative Companies list four times [4]

Core Insights - Molecular Partners AG is making significant progress in its clinical programs, particularly with MP0712 and MP0533, with key milestones expected in the near future [2][6] - The company has appointed Martin Steegmaier, Ph.D., as Chief Scientific Officer, enhancing its leadership team [2][15] - Financially, the company is in a strong position with cash reserves projected to last until 2028 [2][19] Research & Development Highlights - MP0533 is in a Phase 1/2a trial for acute myeloid leukemia, showing promising results with over 30% of evaluable patients achieving a clinical response [3][4] - The dosing regimen for MP0533 has been optimized to enhance patient responses, with initial data from cohort 9 expected in Q4 2025 [5][6] - MP0712, a Radio-DARPin therapy for small cell lung cancer, is preparing for an IND filing, with initial clinical data anticipated in H1 2026 [8][9] Corporate Governance Highlights - The appointment of Martin Steegmaier, Ph.D., as CSO is aimed at strengthening the company's focus on oncology drug development [15] - A strategic review led to a planned reduction of up to 40 positions, which is expected to improve operational efficiency and extend the cash runway into 2028 [16] Financial and Business Outlook - For 2025, the company expects total operating expenses between CHF 55-65 million, with a significant portion being non-cash costs [18] - As of June 30, 2025, cash and cash equivalents totaled CHF 114 million, sufficient to fund operations into 2028 [19]

Amlan® to Present on Biotoxin Control and Antibiotic-Free Poultry Production at Malaysia Livestock 2025 Amlan International, the animal health business of Oil-Dri® Corporation of America and a global leader in natural feed additives, will participate in Malaysia Livestock 2025 at the Kuala Lumpur Convention Centre from August 27–29 CHICAGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amlan International, the animal health business of Oil-Dri® Corporation of America and a global leader in natural feed additives, w ...

São Paulo, Brazil, Aug. 25, 2025 (GLOBE NEWSWIRE) -- GWM officially inaugurated its Brazil Plant in Iracemápolis, São Paulo, marking its first full-process manufacturing hub in South America. With annual production capacity set to grow from 20,000 to 50,000 vehicles, the plant exemplifies GWM’s “high-quality globalization”strategy—delivering global standards while earning local trust.” Industry analysts describe the Brazil Plant as more than a factory, but a symbol of advanced technology, local adaptation, ...